Business Context and Reporting Period
This Form 8-K Current Report was filed by Processa Pharmaceuticals, Inc. on July 19, 2022. The filing reports a corporate governance event regarding the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the appointment of James R. Neal to the Board of Directors, effective immediately on July 19, 2022. Mr. Neal will serve until the 2023 Annual Meeting of Shareholders or until his death, resignation, or removal.
Management Commentary and Risks
The Board elected Mr. Neal due to his extensive experience in the life sciences industry and with public companies. His current roles include Chief Executive Officer and Chairman of the Board for XOMA, Inc., and Board Director for Palisade Bio, Inc. and Monterey Bio Acquisition Corporation. No specific risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Points
- Verify the terms of Mr. Neal's compensation under the Company's non-employee director program as described in the Proxy Statement filed on May 31, 2022.
- Confirm the effective date of the appointment (July 19, 2022) and the term end date (2023 Annual Meeting).
- Review Mr. Neal's existing board commitments to assess potential time allocation conflicts.